An Integrated Analysis of HAVCR1 with a Focus on Immunological and Prognostic Roles in Breast Cancer.

IF 2.1 Q2 MATHEMATICAL & COMPUTATIONAL BIOLOGY

Cancer Informatics Pub Date : 2025-11-28 eCollection Date: 2025-01-01 DOI:10.1177/11769351251393148

Wen Sun, Weiya Zhang, Jianyi Zhao, Mingyi Sang, Qixuan Feng, Wenbin Zhou, Yue Sun

{"title":"An Integrated Analysis of HAVCR1 with a Focus on Immunological and Prognostic Roles in Breast Cancer.","authors":"Wen Sun, Weiya Zhang, Jianyi Zhao, Mingyi Sang, Qixuan Feng, Wenbin Zhou, Yue Sun","doi":"10.1177/11769351251393148","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer remains a predominant malignancy and a leading cause of oncologic mortality among women globally. The discovery of novel biomarkers is crucial for improving therapeutic outcomes.Methods: We conducted a comprehensive analysis of the immunological and prognostic significance of hepatitis A virus cellular receptor 1 (HAVCR1) in breast cancer using publicly available datasets.Results: HAVCR1 expression was markedly downregulated in breast cancer tissues. Significantly, lower expression levels of HAVCR1 in pre-treatment tumor samples were associated with poorer prognosis among pan-cancer patients undergoing immunotherapy, and a higher incidence of metastasis was observed in the breast cancer subgroup. Subtype-specific DEG analyses further indicated that distinct patterns of immune infiltration may underlie this association. Moreover, gene set enrichment analysis (GSEA) highlighted the immunological relevance of HAVCR1, particularly its involvement in T cell activation within the TNBC subtype. Clinically, elevated levels of HAVCR1 expression in pre-treatment T cells were indicative of a more favorable response to PD-1 blockade therapy compared to those with diminished expression.Conclusion: The expression of HAVCR1 exhibits a strong correlation with immune infiltration and holds potential as a prognostic biomarker for breast cancer, offering predictive insight into the efficacy of immunotherapeutic interventions.","PeriodicalId":35418,"journal":{"name":"Cancer Informatics","volume":"24 ","pages":"11769351251393148"},"PeriodicalIF":2.1000,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12663051/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11769351251393148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer remains a predominant malignancy and a leading cause of oncologic mortality among women globally. The discovery of novel biomarkers is crucial for improving therapeutic outcomes.

Methods: We conducted a comprehensive analysis of the immunological and prognostic significance of hepatitis A virus cellular receptor 1 (HAVCR1) in breast cancer using publicly available datasets.

Results: HAVCR1 expression was markedly downregulated in breast cancer tissues. Significantly, lower expression levels of HAVCR1 in pre-treatment tumor samples were associated with poorer prognosis among pan-cancer patients undergoing immunotherapy, and a higher incidence of metastasis was observed in the breast cancer subgroup. Subtype-specific DEG analyses further indicated that distinct patterns of immune infiltration may underlie this association. Moreover, gene set enrichment analysis (GSEA) highlighted the immunological relevance of HAVCR1, particularly its involvement in T cell activation within the TNBC subtype. Clinically, elevated levels of HAVCR1 expression in pre-treatment T cells were indicative of a more favorable response to PD-1 blockade therapy compared to those with diminished expression.

Conclusion: The expression of HAVCR1 exhibits a strong correlation with immune infiltration and holds potential as a prognostic biomarker for breast cancer, offering predictive insight into the efficacy of immunotherapeutic interventions.

Abstract Image

查看原文本刊更多论文

基于乳腺癌免疫和预后作用的HAVCR1的综合分析

背景：乳腺癌仍然是一种主要的恶性肿瘤，也是全球妇女肿瘤死亡率的主要原因。新的生物标志物的发现对于改善治疗效果至关重要。方法：我们利用公开的数据集对甲型肝炎病毒细胞受体1 （HAVCR1）在乳腺癌中的免疫学和预后意义进行了全面分析。结果：HAVCR1在乳腺癌组织中表达明显下调。值得注意的是，在接受免疫治疗的泛癌患者中，治疗前肿瘤样本中较低的HAVCR1表达水平与较差的预后相关，并且在乳腺癌亚组中观察到较高的转移发生率。亚型特异性DEG分析进一步表明，不同的免疫浸润模式可能是这种关联的基础。此外，基因集富集分析（GSEA）强调了HAVCR1的免疫学相关性，特别是它参与TNBC亚型的T细胞活化。临床上，治疗前T细胞中HAVCR1表达水平升高表明与表达降低的T细胞相比，对PD-1阻断治疗的反应更有利。结论：HAVCR1的表达与免疫浸润有很强的相关性，具有作为乳腺癌预后生物标志物的潜力，为免疫治疗干预的疗效提供了预测性见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Informatics Medicine-Oncology

CiteScore

3.00

自引率

5.00%

发文量

审稿时长

8 weeks

期刊介绍： The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.